ReviewClinical and translational radiation oncology2027
Dose-volume predictors of post-radiation xerostomia in head and neck cancer: A systematic review.
Review in Clinical and translational radiation oncology, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Radiation-induced xerostomia remains a major toxicity after radiotherapy for head and neck cancer (HNC). Although QUANTEC-based parotid dose constraints are widely applied, increasing evidence suggests that additional salivary and oral structures may contribute to xerostomia risk. This systematic review aimed to summarize contemporary evidence on dose-volume predictors of post-radiotherapy xerostomia in HNC. Materials and methods: This PRISMA-based systematic review was registered in PROSPERO (CRD42024519338). PubMed, Embase, Cochrane Library, and Web of Science were searched for studies published between January 2013 and August 2025. Studies evaluating dose-volume predictors of xerostomia in adult HNC patients treated with curative-intent radiotherapy were included. Results: Fifty-one studies involving 10,789 patients were included. Most patients received intensity-modulated radiotherapy. Contralateral parotid gland mean dose (Dmean) was the most consistently validated predictor of xerostomia and was supported by moderate-certainty evidence. Multiple studies reported increased risk of moderate-to-severe xerostomia when contralateral parotid Dmean exceeded 24-26 Gy, whereas Dmean below 20 Gy was associated with better salivary preservation. Bilateral parotid Dmean around 26 Gy was also reported. However, support for specific numerical planning thresholds remained limited. Dosimetric parameters of the submandibular glands and oral cavity were also independently associated with xerostomia risk. Emerging evidence suggested potential roles of parotid substructures, including ducts and stem cell-rich regions. Conclusion: Parotid gland mean dose remains the most robust predictor of post-radiotherapy xerostomia in HNC. Additional dosimetric information from the submandibular glands, oral cavity, and parotid substructures may further improve xerostomia risk stratification and support future NTCP modeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.